Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo


Newell P., Toffanin S., Villanueva A., Chiang D. Y. , Minguez B., Cabellos L., et al.

JOURNAL OF HEPATOLOGY, cilt.51, ss.725-733, 2009 (SCI İndekslerine Giren Dergi)

  • Cilt numarası: 51 Konu: 4
  • Basım Tarihi: 2009
  • Doi Numarası: 10.1016/j.jhep.2009.03.028
  • Dergi Adı: JOURNAL OF HEPATOLOGY
  • Sayfa Sayısı: ss.725-733

Özet

Background/Aims: The success of sorafenib in the treatment of advanced hepatocellular carcinoma (HCC) has focused interest on the role of Ras signaling in this malignancy. We investigated the molecular alterations of the Ras pathway in HCC and the antineoplastic effects of sorafenib in combination with rapamycin, an inhibitor of mTOR pathway, in experimental models.